Squeeze for French doctors and drugs, as health insurance fund shows muscle

30 January 2006

The board of the French national union of health insurance funds (Uncam) has set out its recommendations to its director, Frederic van Roekeghem, on the progress of talks with doctors over the extent of spending on fees and treatments through 2006. Fee increases adopted by Uncam in 2005 in favor of doctors, will result in increased pay-ments of 260.0 million euros ($315.1 million) in 2006 .

The room for maneuver in current talks is constrained by financial limits set by the French parliament, making independent general practitioners' demands for increases in consultation fees impossible to satisfy. Uncam's board notes that its priority is to avoid any overspending beyond 0.75% of its budgetary targets, as this would trigger an emergency mechanism, whereby automatic cutbacks would kick in.

Running hospitals is the government's job?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight